Full Press Release Details
IceCure Receives Notice of Patent Allowance
in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
| Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed | ||
| Cryogenic flow control enhances the efficacy and precision of cryoablation procedures |
CAESAREA, Israel, March 12, 2024 -
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense System,
a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced
it has received a Notice of Allowance from the Japan Patent Office (the "JPO") for its patent application titled "Cryogen
Flow Control". Once granted, the patent will be in effect until 2042. A patent for this invention is pending approval in European
Union, the U.S., and other major markets.
Precise temperature control is crucial for efficacy
and tissue safety in cryoablation procedures. Cryogenic flow control achieves this by utilizing sensor data to regulate the flow of cryogens,
ensuring the desired temperature is reached and maintained at the distal tip of catheters and probes. This optimized cryogenic delivery
enhances treatment effectiveness in cryoablation procedures. Advanced cryogen flow control systems may also offer functionalities, such
as navigation and mapping support within the patient's anatomy, and be incorporated into a wide range of cryosurgical tools.
"We believe that cryogen flow control will
be instrumental in enabling practitioners to perform accurate navigation and cryo-mapping to achieve cryoablation efficiency and expand
cryoablation treatment to more clinical applications in the future," stated Eyal Shamir, IceCure's Chief Executive Officer.
"As a leader in cryoablation technology worldwide, we continue to innovate and build our IP portfolio. This Notice of Allowance
in Japan further fortifies our position in an important market, served in partnership with our in-country distributor, Terumo."
The ProSense Cryoablation System
provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid
nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney,
ProSense enhances patient and
provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid
nitrogen utilization, ProSense opens that door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets
ProSense , an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by
freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective
alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
Forward Looking Statements
This press release contains forward-looking statements
within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking
statements. For example, the Company uses forward-looking statements when it discusses that advanced cryogen flow control systems may
also offer other and that the Company believes that cryogen flow control will be instrumental in enabling practitioners to perform accurate
navigation and cryo-mapping, that the Company is continuing to innovate and build its IP portfolio and that this Notice of Allowance in
Japan further fortifies the Company's position in Japan. Historical results of scientific research and clinical and preclinical
trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its
ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the
United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners;
the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose
and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in
Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the SEC on March 29, 2023, and other documents filed with or furnished to the SEC which are available on
the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date
of this release, except as required by law.